Clinical Trials

Clinical Trial Detail

Return to search results.

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Complete title: A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL)

Research Study Number       20110853
Principal Investigator       Andrei Shustov, MD
Phase       II

Look up trial at NIH

Research Study Description

This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A). The study will also evaluate the safety and efficacy of brentuximab vedotin in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Part B) as well as further evaluate correlation of CD30 expression and response in DLBCL (Part C).

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number       20110853
Contact       Seattle Cancer Care Alliance Intake Office
Telephone       800-804-8824 / 206-288-1024

Hematologic Malignancies; Lymphoma; Non-Hodgkin's Lymphoma (NHL)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials